Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system.
Elsa How Shing KoyPierre LabaugeAthan BailletClément PratiHubert MarotteYves-Marie PersPublished in: Therapeutic advances in musculoskeletal disease (2021)
Tumor necrosis factor alpha (TNF-α) and interleukin-17 (IL-17) are two pro-inflammatory cytokines involved in the pathophysiology of spondyloarthritis (SpA). Therapies targeting TNF-α or IL-17 are used as a second line among SpA patients failing non-steroidal anti-inflammatory drugs. The choice of such treatment has to take into account the patient's comorbidities. Neurologic diseases are common and their association with SpA deserves to be studied. Therefore, the role of TNF-α and IL-17 cytokines is worth investigating in these neuropsychiatric diseases. This review aimed to explore the role of TNF-α and IL-17 in the pathogenesis of uveitis, multiple sclerosis, neuromyelitis optica, Alzheimer's disease, Parkinson's disease and depression. This update is critical to guide the therapeutic management of these co-morbidities in SpA patients.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- multiple sclerosis
- anti inflammatory drugs
- ejection fraction
- ankylosing spondylitis
- newly diagnosed
- disease activity
- peritoneal dialysis
- prognostic factors
- depressive symptoms
- systemic lupus erythematosus
- white matter
- physical activity
- patient reported
- solid state
- smoking cessation